Close

Heron Therapeutics (HRTX) to Present Statistically Significant HTX-011 Phase 2 Data at PAINWeek

September 8, 2016 9:03 AM EDT Send to a Friend
Heron Therapeutics, Inc. (Nasdaq: HRTX) announced that results from the initial portions of Heron’s Phase 2 study of HTX-011 in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login